

**UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF ILLINOIS  
EASTERN DIVISION**

SECURITIES AND EXCHANGE COMMISSION,	)	
	)	
Plaintiff,	)	Civil Action No. 11-cv-5223
	)	
v.	)	
	)	HON. ELAINE E. BUCKLO
STEPHEN D. FERRONE, DOUGLAS A. MCCLAIN, JR., DOUGLAS A. MCCLAIN, SR., JAMES T. MICELI, IMMUNOSYN CORPORATION, ARGYLL BIOTECHNOLOGIES, LLC, ARGYLL EQUITIES, LLC, AND PADMORE HOLDINGS, LTD.,	)	
	)	
Defendants.	)	
	)	

**FINAL JUDGMENT AS TO DEFENDANT DOUGLAS MCCLAIN JR.**

This cause comes before the Court upon Plaintiff United States Securities and Exchange Commission’s (“SEC”) Motion for Partial Summary Judgment (“Motion”) as to Defendant Douglas McClain Jr. (“McClain Jr.”). The Court has considered the Motion, the memorandum of law, declarations, and exhibits filed in support of the Motion, and having been fully advised in the premises, finds:

1. That this Court has jurisdiction over the subject matter of this case and there is good cause to believe it will have jurisdiction over all parties hereto;
2. That the Court granted in part and denied in part the SEC’s Motion in a Memorandum Opinion and Order dated October 21, 2015. *See* Docket Entry No. 189.
3. That entry of a Final Judgment against Defendant McClain Jr. is appropriate under Fed. R. Civ. P. 58;

6. That the injunctive and equitable relief Plaintiff seeks against Defendant is adequately supported in fact and law

7. That therefore, the following Order issued:

**I.**

**Entry of Judgment**

IT IS HEREBY ORDERED, ADJUDGED, AND DECREED that, pursuant to Fed. R. Civ. P. 58, judgment is hereby entered against Defendant McClain Jr.

IT IS FURTHER ORDERED, ADJUDGED, AND DECREED the Court finds in favor of the Plaintiff on all factual allegations and causes of action that were asserted by Plaintiff in its Complaint and that Plaintiff has not previously voluntarily dismissed against Defendant McClain Jr.

**II.**

**Permanent Injunction Against Violations of Section 17(a) of the Securities Act**

IT IS FURTHER ORDERED, ADJUDGED, AND DECREED that Defendant McClain Jr. and his agents, servants, employees, attorneys, and all persons in active concert or participation with them who receive actual notice of this Final Judgment by personal service or otherwise, are permanently restrained and enjoined from violating Section 17(a) of the Securities Act of 1933 (the "Securities Act") [15 U.S.C. § 77q(a)], by, in the offer or sale of any security, using any means or instruments of transportation or communication in interstate commerce or by using the mails, directly or indirectly:

- (1) to employ any device, scheme, or artifice to defraud;
- (2) to obtain money or property by means of any untrue statement of a material fact or any omission of a material fact necessary in order to make the statements

made, in light of the circumstances under which they were made, not misleading;  
or

- (3) to engage in any transaction, practice, or course of business which operates or would operate as a fraud or deceit upon the purchaser.

### **III.**

#### **Permanent Injunction Against Violations of Section 10(b) of the Exchange Act and Rule 10b-5 Thereunder**

IT IS FURTHER ORDERED, ADJUDGED, AND DECREED that Defendant McClain Jr. and his agents, servants, employees, attorneys, and those persons in active concert or participation with them, and each of them who receive actual notice of this Final Judgment by personal service or otherwise, are permanently restrained and enjoined from violating, directly or indirectly, Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”) [15 U.S.C. § 78j(b)], and Rule 10b-5 promulgated thereunder [17 CFR § 240.10b-5], by using any means or instrumentality of interstate commerce, or of the mails, or of any facility of any national securities exchange, in connection with the purchase or sale of any security:

- (a) to employ any device, scheme, or artifice to defraud;
- (b) to make any untrue statement of a material fact or to omit to state a material fact necessary in order to make the statements made, in the light of the circumstances under which they were made, not misleading; or
- (c) to engage in any act, practice, or course of business which operates or would operate as a fraud or deceit upon any person.

**IV.**

**[BIOPHARMACEUTICAL COMPANY OFFICER AND DIRECTOR BAR]**

IT IS FURTHER ORDERED, ADJUDGED, AND DECREED that, pursuant to Section 21(d)(2) of the Exchange Act [15 U.S.C. § 78u(d)(2)] Defendant is prohibited from acting as an officer or director of any biopharmaceutical company issuer that has a class of securities registered pursuant to Section 12 of the Exchange Act [15 U.S.C. § 78l] or that is required to file reports pursuant to Section 15(d) of the Exchange Act [15 U.S.C. § 78o(d)].

**VI.**

**Retention of Jurisdiction**

IT IS FURTHER ORDERED, ADJUDGED, AND DECREED that this Court shall retain jurisdiction of this matter for the purposes of enforcing the terms of this Final Judgment.

**SO ORDERED** this 14th day of January, 2016.



---

HON. ELAINE E. BUCKLO